Skip to main content

Table 1 Characteristics of patients recruited up to July 2016 (n = 1636)

From: Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme

Characteristic Number (%) or mean ± SD
Patient number 1636
Gender (female:male) 6.4:1 (86.1% vs 13.9%)
Race
 Caucasian 1390 (91.9%)
 Asian 75 (4.9%)
 Aboriginal-Islander 18 (1.2%)
 Hispanic 11 (0.7%)
 Other 19 (1.3%)
Age at recruitment, mean ± SD, years 57.2 ± 12.8
Disease duration at recruitmenta, years 10.9 ± 10.2
Recruited within 4 years of first non-Raynaud’s feature 435
Age at diagnosis of PAH if present, years 62.9 ± 11.1
Number of study visits
 One 364 (22.3%)
 Two 325 (19.9%)
 Three 216 (13.2%)
 Four 199 (12.2%)
 Five 165 (10.1%)
 Six 119 (7.3%)
 Seven 71 (4.3%)
 Eight 79 (4.8%)
 Nine 84(5.2%)
 Ten 14 (0.9%)
Duration of follow up, mean ± SD, years 3.7 ± 2.7
Patient status
 Current 1243 (76.5%)
 Withdrawn 101 (6.2%)
 Dead 220 (13.5%)
 Lost to follow up 61 (3.8%)
Disease subtype
 Limited 1122 (68.6%)
 Diffuse 377 (23.0%)
 MCTD 83 (5.3%)
Autoantibody profile
 ANA positive (n = 1508) 1418 (94.0%)
 Anti-centromere (n = 1497) 673 (44.9%)
 Anti-Scl70 (n = 1483) 205 (13.8%)
 Anti-RNAP (n = 794) 125 (13.1%)
  1. aDisease duration from first non-Raynaud manifestation. Numbers of variables analysed (n =) are included in each section of the table to acknowledge any missing data. Patient status: current patients were defined as being seen in the last 2 years, withdrawn patients have withdrawn their consent from participating in the database and lost to follow up is defined as patients who, despite multiple attempts, we have been unable to contact for >18 months. PAH pulmonary arterial hypertension, MCTD mixed connective tissue disease, ANA antinuclear antibody, Anti-RNAP anti-RNA polymerase